For research use only. Not for therapeutic Use.
XEN723 is a novel and potent thiazolylimidazolidinone inhibitor of Stearoyl-CoA Desaturase (SCD1) with IC50s of 45 and 524 nM in mouse and HepG2 cell, respectively.
XEN723 is a novel and potent thiazolylimidazolidinone inhibitor of Stearoyl-CoA Desaturase (SCD1) with IC50s of 45 and 524 nM in mouse and HepG2 cell, respectively. XEN723 demonstrates an improvement in SCD1 in vitro potency of more than 560-fold compare to the original high throughput screen (HTS) hit[1].
| Catalog Number | I020367 |
| CAS Number | 1072803-08-7 |
| Synonyms | 2-[3-[(4-fluorophenyl)methyl]-2-oxoimidazolidin-1-yl]-4-methyl-N-(pyridin-3-ylmethyl)-1,3-thiazole-5-carboxamide |
| Molecular Formula | C21H20FN5O2S |
| Purity | ≥95% |
| InChI | InChI=1S/C21H20FN5O2S/c1-14-18(19(28)24-12-16-3-2-8-23-11-16)30-20(25-14)27-10-9-26(21(27)29)13-15-4-6-17(22)7-5-15/h2-8,11H,9-10,12-13H2,1H3,(H,24,28) |
| InChIKey | OVFKEMNMAWPWAV-UHFFFAOYSA-N |
| SMILES | CC1=C(SC(=N1)N2CCN(C2=O)CC3=CC=C(C=C3)F)C(=O)NCC4=CN=CC=C4 |
| Reference | [1]. Sun S, et al. Systematic evaluation of amide bioisosteres leading to the discovery of novel and potent thiazolylimidazolidinone inhibitors of SCD1 for the treatment of metabolic diseases. Bioorg Med Chem Lett. 2014 Jan 15;24(2):520-5. |
